COMBAT - Updated biosecurity tool with 4 features
Read now
The Guilty Gilt Guide
Read now
PRRS Ctrl 2.0
Download for free
The 11th European PRRS Research Awards
Discover now
COMBAT - Updated biosecurity tool with 4 features
The Guilty Gilt Guide
PRRS Ctrl 2.0
The 11th European PRRS Research Awards
May 2024
18
19
20
21
22
23
24
25
26
27
28
29
30
31
June 2024
01
02
03
04
05
06
07
08
09
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
July 2024
01
02
03
04
05
06
07
08
09
10
11
12
13
14
15
16
17
18
Poster Abstracts
- 4 minutes, 31 seconds
- Expertise article
- A. Patterson*, G. Haiwick, J. Victoria, J. Hermann, R. Philips
Poster Abstracts
Evaluating dry vs. wet disinfection in boot baths on detection of porcine epidemic diarrhea virus and porcine reproductive and respiratory virus RNA
- Top 3 Publications of the month | March 2023 | Expertise article
- Olivia L Harrison et al.
Maintaining biosecurity between swine barns is challenging, and boot baths are an easily implementable option some utilize to limit pathogen spread.
Evaluation of a 20 year old porcine reproductive and respiratory syndrome (PRRS) modified live vaccine (Ingelvac® PRRS MLV) against two recent type 2 PRRS virus isolates in South Korea
- 2 minutes
- Expertise article
Type 2 porcine reproductive and respiratory syndrome (PRRS) virus (PRRSV) was first isolated in Korea in 1994. The commercial PRRS modified live vaccine (Ingelvac® PRRS MLV, Boehringer Ingelheim Vetmedica Inc., St. Joseph, Missouri, USA) based on type 2 PRRSV, was first licensed for use in 3- to 18-week-old pigs in Korea in 1996. The objective of the present study was to evaluate the efficacy of this 20 year old commercial PRRS modified live vaccine (MLV) against two recent PRRSV isolates. Two genetically distant type 2 PRRSV strains (SNUVR150004 for lineage 1 and SNUVR150324 for lineage 5), isolated in 2015, were used as challenge virus. Regardless of the challenge virus, vaccination of pigs effectively reduced the level of viremia, the lung lesions, and of the PRRSV antigen within the lung lesions. The induction of virus-specific interferon-γ secreting cells by the PRRS vaccine produced a protective immune response, leading to the reduction of PRRSV viremia. There were no significant differences in efficacy against the two recently isolated viruses by the PRRS MLV based on virological results, immunological responses, and pathological outcomes. This study demonstrates that the PRRS MLV used in this study is still effective against recently isolated heterologous type 2 PRRSV strains even after 20 years of use in over 35 million pigs.
Case control and management of virulent PRRS in a commercial farm in the Philippines
- 10 minutes
- Expertise article | IPVS 2010
- A. A. C. Manabat. IPVS.2010
Despite dramatic improvements, the farm is still a case-control in progress, vaccinating with lngelvac PRRS MLV just barely 6 months as of data avallability
Don’t miss any news on PRRS disease control Subscribe now to PRRS.com newsletter
Accidental Pig Vaccine Injection Injury
- Top 3 Publications of the month | April
- Robert E. Van Demark Jr. et al.
Animal vaccine injection injuries of the hand are of special concern in veterinary medicine and agricultural fields.
Investigation and evaluation of alternate PRRS vaccine options to enhance immunostimulation and increased protection
- Expertise article
- Zuckermann et al., 2008 (study 8)
Investigators – Zuckerman; Roof; Vaughn; Wes Johnson (BIVI – U. Illinois Collaboration)
Comparison of Two Commercial Type 1 Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) Modified Live Vaccines against Heterologous Type 1 and Type 2 PRRSV Challenge in Growing Pigs
- 2 minutes
- Expertise article
The objective of the present study was to compare the efficacy of two commercial type 1 porcine reproductive and respiratory syndrome virus (PRRSV) modified live vaccines against heterologous type 1 and type 2 PRRSV challenge in growing pigs. Vaccination with a type 1 PRRSV vaccine reduced the level of viremia after type 1 PRRSV challenge but did not reduce the level of viremia after the type 2 PRRSV challenge in pigs. Increased levels of interleukin-10 (IL-10) stimulated by type 2 PRRSV coincided with the low numbers of type 2 PRRSV-specific interferon gamma-secreting cells (IFN-γ-SC) in vaccinated pigs after type 2 PRRSV challenge, whereas low levels of IL-10 stimulated by type 1 PRRSV coincided with high numbers of type 1 PRRSV-specific IFN-γ-SC in vaccinated pigs after type 1 PRRSV challenge. Additionally, vaccination with the type 1 PRRSV vaccine effectively reduced the lung lesions and type 1 PRRSV nucleic acids in type 1 PRRSV-challenged pigs but did not reduce lung lesions and type 2 PRRSV nucleic acids in type 2 PRRSV-challenged pigs. There were no significant differences between two commercial type 1 PRRSV vaccines against type 1 and type 2 PRRSV challenge based on virological results, immunological responses, and pathological outcomes. This study demonstrates that vaccinating pigs with the type 1 PRRSV vaccine provides partial protection against respiratory disease with heterologous type 1 PRRSV challenge but no protection with heterologous type 2 PRRSV challenge.
Michael Murtaugh - Global PRRSpective
- 44 minutes
- Control | Expertise video
- Michael Murtaugh
How does PRRS interact with the pig and how do pigs respond to the infection? These and many more questions are answered by Prof Michael Murthaugh.